Partner Research Centers:


Alzheimer’s Disease Core Center

Publications

Featured Publication

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults

October 2017 | Jessica Mozersky, PhD, Pamela Sankar, PhD, Kristin Karkins, MPH, et. al.

ABSTRACT:
Importance:  The goal of Alzheimer disease (AD) prevention together with advances in understanding the pathophysiology of AD have led to clinical trials testing drugs in cognitively unimpaired persons who show evidence of AD biomarkers. Data are needed to inform the processes of describing AD biomarkers to cognitively normal adults and assessing their understanding of this knowledge.

Objective:  To determine the comprehension of an elevated amyloid positron emission tomographic (PET) biomarker result by cognitively unimpaired adults.

Design, Setting, and Participants:  The Study of Knowledge and Reactions to Amyloid Testing, a substudy of an AD prevention trial, involved 2 semistructured telephone interviews with 80 participants recruited from 9 study sites: 50 received elevated and 30 received not elevated amyloid PET scan results. Interviews were conducted 4 to 12 weeks after result disclosure and again 1 year later. Data presented here were collected from November 5, 2014, through December 10, 2015. The 50 participants included in this study were cognitively normal, aged 65 to 85 years, evenly distributed by gender, and had elevated amyloid PET results. Subsequent reports will examine persons with “not elevated” results and compare the influence of the different results.

Main Outcomes and Measures:  Participant comprehension of an elevated amyloid result was assessed by analyzing their responses to the following questions: “What was the result of your amyloid PET scan?” (followed by “Can you tell me in your own words what that means?” or “How would you explain it to a friend?”), “Was it the result you expected?” and “Did the result teach you anything or clarify anything for you?”

Results:  Of the 50 participants aged 65 to 85 years, 49 (98%) were white, 40 (80%) reported a family history of AD, and 30 (60%) had a postgraduate educational level. Most participants (31 [62%]) understood that elevated amyloid conferred an increased but uncertain risk of developing AD. Some desired understanding of the term elevated other than its being a categorical result enabling trial entry eligibility; they wanted information regarding how elevated their amyloid was, how close to the study threshold they were, or percentages, numbers, or a scale to help them make sense of the result.

Conclusions and Relevance:  Including an explanation of how and why a dimensional biomarker is converted to a categorical classification would enhance future AD biomarker clinical trials and educational materials.

Full JAMA Neurology Publication

Full Penn Medicine News Release 

Close section


More Publications

Ante mortem CSF tau levels correlate with post mortem tau pathology in FTLD.

Ann Neurol. 2017 Jul 18; Authors: Irwin DJ, Lleó A, Xie SX, McMillan CT, Wolk D, Lee EB, Van Deerlin VM, Shaw LM, Trojanowski JQ, Grossman M


Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.

Nat Genet. 2017 Jul 17Authors: Wang LS, Lambert JC, Seshadri S, Williams J, Schellenberg GD, et. al.


TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss.

Neuron. 2017 Jun 27; Authors: Paolicelli RC, Jawaid A, Henstridge CM, Valeri A, Merlini M, Robinson JL, Lee EB, Rose J, Appel S, Lee VM, Trojanowski JQ, Spires-Jones T, Schulz PE, Rajendran L


Clinically silent Alzheimer's and vascular pathologies influence brain networks supporting executive function in healthy older adults.

Neurobiol Aging. 2017 Jun 24; Authors: Gold BT, Brown CA, Hakun JG, Shaw LM, Trojanowski JQ, Smith CD


Effects of cognitive reserve depend on executive and semantic demands of the task.

J Neurol Neurosurg Psychiatry. 2017 Jun 19; Authors: Darby RR, Brickhouse M, Wolk DA, Dickerson BC, Alzheimer’s Disease Neuroimaging Initiative


Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG).

J Neuropathol Exp Neurol. 2017 Jun 07; Authors: Kovacs GG, Xie SX, Lee EB, Robinson JL, Caswell C, Irwin DJ, Toledo JB, Johnson VE, Smith DH, Alafuzoff I, Attems J, Bencze J, Bieniek KF, Bigio EH, Bodi I, Budka H, Dickson DW, Dugger BN, Duyckaerts C, Ferrer I, Forrest SL, Gelpi E, Gentleman SM, Giaccone G, Grinberg LT, Halliday GM, Hatanpaa KJ, Hof PR, Hofer M, Hortobágyi T, Ironside JW, King A, Kofler J, Kövari E, Kril JJ, Love S, Mackenzie IR, Mao Q, Matej R, McLean C, Munoz DG, Murray ME, Neltner J, Nelson PT, Ritchie D, Rodriguez RD, Rohan Z, Rozemuller A, Sakai K, Schultz C, Seilhean D, Smith V, Tacik P, Takahashi H, Takao M, Rudolf Thal D, Weis S, Wharton SB, White CL, Woulfe JM, Yamada M, Trojanowski JQ


Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.

J Alzheimers Dis. 2017 May 25; Authors: Deters KD, Risacher SL, Kim S, Nho K, West JD, Blennow K, Zetterberg H, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ, Alzheimer Disease Neuroimaging Initiative


Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.

BMC Med Genomics. 2017 May 24; Authors: Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR, Weiner MW, Green RC, Toga AW, Saykin AJ, Alzheimer’s Disease Neuroimaging Initiative (ADNI)


Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia.

Neurology. 2017 May 17; Authors: Giannini LAA, Irwin DJ, McMillan CT, Ash S, Rascovsky K, Wolk DA, Van Deerlin VM, Lee EB, Trojanowski JQ, Grossman M


Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

Alzheimers Res Ther. 2017 May 04; Authors: Grill JD, Apostolova LG, Bullain S, Burns JM, Cox CG, Dick M, Hartley D, Kawas C, Kremen S, Lingler J, Lopez OL, Mapstone M, Pierce A, Rabinovici G, Roberts JS, Sajjadi SA, Teng E, Karlawish J


Predictive indices for functional improvement and deterioration, institutionalization, and death among elderly Medicare beneficiaries.

PM R. 2017 Apr 26; Authors: Kurichi JE, Kwong PL, Xie D, Bogner HR


Expanding engagement with the ethical implications of changing definitions of Alzheimer's disease.

Lancet Psychiatry. 2017 Apr; Authors: Milne R, Karlawish J


Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Alzheimers Dement. 2017 Mar 22; Authors: Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative


Metabolic network failures in Alzheimer's disease-A biochemical road map.

Alzheimers Dement. 2017 Mar 21; Authors: Toledo JB, Arnold M, Kastenmüller G, Chang R, Baillie RA, Han X, Thambisetty M, Tenenbaum JD, Suhre K, Thompson JW, John-Williams LS, MahmoudianDehkordi S, Rotroff DM, Jack JR, Motsinger-Reif A, Risacher SL, Blach C, Lucas JE, Massaro T, Louie G, Zhu H, Dallmann G, Klavins K, Koal T, Kim S, Nho K, Shen L, Casanova R, Varma S, Legido-Quigley C, Moseley MA, Zhu K, Henrion MY, van der Lee SJ, Harms AC, Demirkan A, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Saykin AJ, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R, Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium


Cognitive decline associated with pathological burden in primary age-related tauopathy.

Alzheimers Dement. 2017 Mar 16; Authors: Jefferson-George KS, Wolk DA, Lee EB, McMillan CT


Alzheimer's disease: The next frontier-Special Report 2017.

Alzheimers Dement. 2017 Mar 14; Authors: Karlawish J, Jack CR, Rocca WA, Snyder HM, Carrillo MC


Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Acta Neuropathol. 2017 Feb 28; Authors: Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Huang KL, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Kim S, Saykin AJ, De Jager PL, Albert M, Moghekar A, O'Brien R, Riemenschneider M, Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Schellenberg G, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Peskind ER, Li G, Di Narzo AF, Alzheimer’s Disease Neuroimaging Initiative (ADNI), Alzheimer Disease Genetic Consortium (ADGC), Kauwe JS, Goate AM, Cruchaga C


Bridging cognitive screening tests in neurologic disorders: A crosswalk between the short Montreal Cognitive Assessment and Mini-Mental State Examination.

Alzheimers Dement. 2017 Feb 23; Authors: Roalf DR, Moore TM, Mechanic-Hamilton D, Wolk DA, Arnold SE, Weintraub DA, Moberg PJ


Approach to atypical Alzheimer's disease and case studies of the major subtypes.

CNS Spectr. 2017 Feb 15; Authors: Dickerson BC, McGinnis SM, Xia C, Price BH, Atri A, Murray ME, Mendez MF, Wolk DA


Transethnic genome-wide scan identifies novel Alzheimer's disease loci.

Alzheimers Dement. 2017 Feb 06; Authors: Jun GR, Chung J, Mez J, Barber R, Beecham GW, Bennett DA, Buxbaum JD, Byrd GS, Carrasquillo MM, Crane PK, Cruchaga C, De Jager P, Ertekin-Taner N, Evans D, Fallin MD, Foroud TM, Friedland RP, Goate AM, Graff-Radford NR, Hendrie H, Hall KS, Hamilton-Nelson KL, Inzelberg R, Kamboh MI, Kauwe JS, Kukull WA, Kunkle BW, Kuwano R, Larson EB, Logue MW, Manly JJ, Martin ER, Montine TJ, Mukherjee S, Naj A, Reiman EM, Reitz C, Sherva R, St George-Hyslop PH, Thornton T, Younkin SG, Vardarajan BN, Wang LS, Wendlund JR, Winslow AR, Alzheimer's Disease Genetics Consortium, Haines J, Mayeux R, Pericak-Vance MA, Schellenberg G, Lunetta KL, Farrer LA


Milder Alzheimer's disease pathology in heart failure and atrial fibrillation.

Alzheimers Dement. 2017 Feb 04; Authors: Sposato LA, Ruíz Vargas E, Riccio PM, Toledo JB, Trojanowski JQ, Kukull WA, Cipriano LE, Nucera A, Whitehead SN, Hachinski V


Typical and atypical pathology in primary progressive aphasia variants.

Ann Neurol. 2017 Jan 30; Authors: Spinelli EG, Mandelli ML, Miller ZA, Santos-Santos MA, Wilson SM, Agosta F, Grinberg LT, Huang EJ, Trojanowski JQ, Meyer M, Henry ML, Comi G, Rabinovici G, Rosen HJ, Filippi M, Miller BL, Seeley WW, Gorno-Tempini ML


Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies.

ACS Chem Neurosci. 2017 Jan 18; Authors: Ballatore C, Brunden KR, Trojanowski JQ, Lee VM, Smith AB


Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Brain. 2017 Jan 12; Authors: Ono M, Sahara N, Kumata K, Ji B, Ni R, Koga S, Dickson DW, Trojanowski JQ, Lee VM, Yoshida M, Hozumi I, Yoshiyama Y, van Swieten JC, Nordberg A, Suhara T, Zhang MR, Higuchi M


Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders.

Front Hum Neurosci. 2016; Authors: Spotorno N, McMillan CT, Irwin DJ, Clark R, Lee EB, Trojanowski JQ, Weintraub D, Grossman M


Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.

Lancet Neurol. 2017 Jan; Authors: Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Woltjer R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ


A quantitative meta-analysis of olfactory dysfunction in mild cognitive impairment.

J Neurol Neurosurg Psychiatry. 2016 Dec 30; Authors: Roalf DR, Moberg MJ, Turetsky BI, Brennan L, Kabadi S, Wolk DA, Moberg PJ


Identifiable Characteristics and Potentially Malleable Beliefs Predict Stigmatizing Attributions Toward Persons With Alzheimer's Disease Dementia: Results of a Survey of the U.S. General Public.

Health Commun. 2016 Dec 29; Authors: Stites SD, Johnson R, Harkins K, Sankar P, Xie D, Karlawish J


Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs.

Neurobiol Dis. 2016 Dec 21; Authors: Brunden KR, Lee VM, Smith AB, Trojanowski JQ, Ballatore C


Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.

Brain. 2016 Dec 20; Authors: Dong A, Toledo JB, Honnorat N, Doshi J, Varol E, Sotiras A, Wolk D, Trojanowski JQ, Davatzikos C, Alzheimer’s Disease Neuroimaging Initiative


Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.

Acta Neuropathol. 2016 Dec 08; Authors: Chapuis J, Flaig A, Grenier-Boley B, Eysert F, Pottiez V, Deloison G, Vandeputte A, Ayral AM, Mendes T, Desai S, Goate AM, Kauwe JS, Leroux F, Herledan A, Demiautte F, Bauer C, Checler F, Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Albert M, Moghekar A, O'Brien R, Peskind ER, Malmanche N, Schellenberg GD, Dourlen P, Song OR, Cruchaga C, Amouyel P, Deprez B, Brodin P, Lambert JC, ADGC, Alzheimer’s Disease Neuroimaging Initiative


Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease.

Neuroimage Clin. 2017; Authors: Brown CA, Johnson NF, Anderson-Mooney AJ, Jicha GA, Shaw LM, Trojanowski JQ, Van Eldik LJ, Schmitt FA, Smith CD, Gold BT


Odor Identification Screening Improves Diagnostic Classification in Incipient Alzheimer's Disease.

J Alzheimers Dis. 2016 Nov 18; Authors: Quarmley M, Moberg PJ, Mechanic-Hamilton D, Kabadi S, Arnold SE, Wolk DA, Roalf DR


Plasma tau in Alzheimer disease.

Neurology. 2016 Oct 25; Authors: Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K, ADNI Investigators


Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.

J Exp Med. 2016 Oct 17; Authors: Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, Gathagan RJ, Iba M, McBride JD, Trojanowski JQ, Lee VM


Multi-Template Analysis of Human Perirhinal Cortex in Brain MRI: Explicitly Accounting for Anatomical Variability.

Neuroimage. 2016 Oct 1; Authors: Xie L, Pluta JB, Das SR, Wisse LE, Wang H, Mancuso L, Kliot D, Avants BB, Ding SL, Manjón JV, Wolk DA, Yushkevich PA


Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Alzheimers Dement. 2016 Oct; Authors: Khanna MR, Kovalevich J, Lee VM, Trojanowski JQ, Brunden KR


Medial temporal lobe subregional morphometry using high resolution MRI in Alzheimer's disease.

Neurobiol Aging. 2016 Sep 30; Authors: Wolk DA, Das SR, Mueller SG, Weiner MW, Yushkevich PA, Alzheimer's Disease Neuroimaging Initiative


Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy.

Acta Neuropathol Commun. 2016; Authors: Makani V, Zhang B, Han H, Yao Y, Lassalas P, Lou K, Paterson I, Lee VM, Trojanowski JQ, Ballatore C, Smith AB, Brunden KR


Gene expression elucidates functional impact of polygenic risk for schizophrenia.

Nat Neurosci. 2016 Sep 26; Authors: Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, Ruderfer DM, Oh EC, Topol A, Shah HR, Klei LL, Kramer R, Pinto D, Gümüş ZH, Cicek AE, Dang KK, Browne A, Lu C, Xie L, Readhead B, Stahl EA, Xiao J, Parvizi M, Hamamsy T, Fullard JF, Wang YC, Mahajan MC, Derry JM, Dudley JT, Hemby SE, Logsdon BA, Talbot K, Raj T, Bennett DA, De Jager PL, Zhu J, Zhang B, Sullivan PF, Chess A, Purcell SM, Shinobu LA, Mangravite LM, Toyoshiba H, Gur RE, Hahn CG, Lewis DA, Haroutunian V, Peters MA, Lipska BK, Buxbaum JD, Schadt EE, Hirai K, Roeder K, Brennand KJ, Katsanis N, Domenici E, Devlin B, Sklar P


Cognitive, social, and neural determinants of diminished decision-making and financial exploitation risk in aging and dementia: A review and new model.

J Elder Abuse Negl. 2016 Sep 20; Authors: Spreng RN, Karlawish J, Marson DC


Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies.

Neurobiol Aging. 2016 Sep 2; Authors: Kun-Rodrigues C, Ross OA, Orme T, Shepherd C, Parkkinen L, Darwent L, Hernandez D, Ansorge O, Clark LN, Honig LS, Marder K, Lemstra A, Scheltens P, van der Flier W, Louwersheimer E, Holstege H, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Trojanowski JQ, Serrano GE, Beach TG, Clarimon J, Lleó A, Morenas-Rodríguez E, Lesage S, Galasko D, Masliah E, Santana I, Diez M, Pastor P, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns NJ, Morris JC, Stone DJ, Pickering-Brown S, Mann D, Dickson DW, Halliday GM, Singleton A, Guerreiro R, Bras J


Structural Correlation-based Outlier Rejection (SCORE) algorithm for arterial spin labeling time series.

J Magn Reson Imaging. 2016 Aug 29; Authors: Dolui S, Wang Z, Shinohara RT, Wolk DA, Detre JA, Alzheimer's Disease Neuroimaging Initiative


Clinical Application of Automatic Segmentation of Medial Temporal Lobe Subregions in Prodromal and Dementia-Level Alzheimer's Disease.
J Alzheimers Dis. 2016 Aug 18; Authors: Gertje EC, Pluta J, Das S, Mancuso L, Kliot D, Yushkevich P, Wolk D

Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease.

BMC Med Genomics. 2016 August 12; Authors: Nho K, Horgusluoglu E, Kim S, Risacher SL, Kim D, Foroud T, Aisen PS, Petersen RC, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, Saykin AJ, ADN


Within-Individual Variability: An Index for Subtle Change in Neurocognition in Mild Cognitive Impairment.

J Alzheimers Dis. 2016 Aug 10; Authors: Roalf DR, Quarmley M, Mechanic-Hamilton D, Wolk DA, Arnold SE, Moberg PJ, Alzheimer’s Disease Neuroimaging Initiative


Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia.

Mov Disord Clin Pract. 2016 Jul-Aug; Authors: Akhtar RS, Xie SX, Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD


Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers.

J Alzheimers Dis. 2016 Jul 25; Authors: Durazzo TC, Korecka M, Trojanowski JQ, Weiner MW, O' Hara R, Ashford JW, Shaw LM, Alzheimer’s Disease Neuroimaging Initiative


"New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS).

J Neuropathol Exp Neurol. 2016 May 21; Authors: Nelson PT, Trojanowski JQ, Abner EL, Al-Janabi OM, Jicha GA, Schmitt FA, Smith CD, Fardo DW, Wang WX, Kryscio RJ, Neltner JH, Kukull WA, Cykowski MD, Van Eldik LJ, Ighodaro ET


Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging.

Ann Clin Transl Neurol. 2016 May 13; Authors: Abner EL, Jicha GA, Shaw LM, Trojanowski JQ, Goetzl EJ


Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease.

J Neurol Neurosurg Psychiatry. 2016 Apr 12; Authors: Roalf DR, Moore TM, Wolk DA, Arnold SE, Mechanic-Hamilton D, Rick J, Kabadi S, Ruparel K, Chen-Plotkin AS, Chahine LM, Dahodwala NA, Duda JE, Weintraub DA, Moberg PJ


Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.

Alzheimers Dement. 2016 Apr; Authors: Rabinovici GD, Karlawish J, Knopman D, Snyder HM, Sperling R, Carrillo MC


Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.

Ann Clin Transl Neurol. 2016 Mar 29; Authors: Lim NS, Swanson CR, Cherng HR, Unger TL, Xie SX, Weintraub D, Marek K, Stern MB, Siderowf A, PARS Investigators, Alzheimer's Disease Neuroimaging Initiative, Trojanowski JQ, Chen-Plotkin AS


Rhythm experience and Africana culture trial (REACT!): A culturally salient intervention to promote neurocognitive health, mood, and well-being in older African Americans.

Contemp Clin Trials. 2016 Mar 28; Authors: Lukach AJ, Jedrziewski MK, Grove GA, Mechanic-Hamilton DJ, Williams SS, Wollam ME, Erickson KI


Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer's disease and related tauopathies.

J Pharmacol Exp Ther. 2016 Mar 15; Authors: Kovalevich J, Cornec AS, Yao Y, James M, Crowe A, Lee VM, Trojanowski JQ, Smith AB, Ballatore C, Brunden KR


Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.

Alzheimers Dement. 2016 Mar 14; Authors: Molinuevo JL, Cami J, Carné X, Carrillo MC, Georges J, Isaac MB, Khachaturian Z, Kim SY, Morris JC, Pasquier F, Ritchie C, Sperling R, Karlawish J


Assessment of the genetic variance of late-onset Alzheimer's disease.

Neurobiol Aging. 2016 Mar 3; Authors: Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane PK, Haines JL, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD, Kauwe JS, Alzheimer's Disease Genetics Consortium (ADGC)


A brain stress test: Cerebral perfusion during memory encoding in mild cognitive impairment.

Neuroimage Clin. 2016 Mar 2; Authors: Xie L, Dolui S, Das SR, Stockbower GE, Daffner M, Rao H, Yushkevich PA, Detre JA, Wolk DA


Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.

Neurobiol Aging. 2016 Mar; Authors: Grill JD, Zhou Y, Elashoff D, Karlawish J


Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease.

J Alzheimers Dis. 2016 Feb 6; Authors: White MT, Shaw LM, Xie SX


An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia.

PLoS One. 2016 Jan 26; Authors: Berlyand Y, Weintraub D, Xie SX, Mellis IA, Doshi J, Rick J, McBride J, Davatzikos C, Shaw LM, Hurtig H, Trojanowski JQ, Chen-Plotkin AS


Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors.

Sci Rep. 2015 Dec 17; Authors: Herbst-Robinson KJ, Liu L, James M, Yao Y, Xie SX, Brunden KR


Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy.

Acta Neuropathol. 2015 Dec 10; Authors: Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, Cairns NJ, Crary JF, Duyckaerts C, Ghetti B, Halliday GM, Ironside JW, Love S, Mackenzie IR, Munoz DG, Murray ME, Nelson PT, Takahashi H, Trojanowski JQ, Ansorge O, Arzberger T, Baborie A, Beach TG, Bieniek KF, Bigio EH, Bodi I, Dugger BN, Feany M, Gelpi E, Gentleman SM, Giaccone G, Hatanpaa KJ, Heale R, Hof PR, Hofer M, Hortobágyi T, Jellinger K, Jicha GA, Ince P, Kofler J, Kövari E, Kril JJ, Mann DM, Matej R, McKee AC, McLean C, Milenkovic I, Montine TJ, Murayama S, Lee EB, Rahimi J, Rodriguez RD, Rozemüller A, Schneider JA, Schultz C, Seeley W, Seilhean D, Smith C, Tagliavini F, Takao M, Thal DR, Toledo JB, Tolnay M, Troncoso JC, Vinters HV, Weis S, Wharton SB, White CL, Wisniewski T, Woulfe JM, Yamada M, Dickson DW


Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals.

JAMA Neurol. 2015 Nov;72(11):1313-23; Authors: Ghani M, Reitz C, Cheng R, Vardarajan BN, Jun G, Sato C, Naj A, Rajbhandary R, Wang LS, Valladares O, Lin CF, Larson EB, Graff-Radford NR, Evans D, De Jager PL, Crane PK, Buxbaum JD, Murrell JR, Raj T, Ertekin-Taner N, Logue M, Baldwin CT, Green RC, Barnes LL, Cantwell LB, Fallin MD, Go RC, Griffith PA, Obisesan TO, Manly JJ, Lunetta KL, Kamboh MI, Lopez OL, Bennett DA, Hendrie H, Hall KS, Goate AM, Byrd GS, Kukull WA, Foroud TM, Haines JL, Farrer LA, Pericak-Vance MA, Lee JH, Schellenberg GD, St George-Hyslop P, Mayeux R, Rogaeva E, Alzheimer’s Disease Genetics Consortium


Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.

JAMA Neurol. 2015 Nov 2; Authors: Zetterberg H, Skillbäck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, Weiner MW, Blennow K, Alzheimer’s Disease Neuroimaging Initiative


Consider the Source: The Implications of Informant Type on Outcome Assessments.

Alzheimer Dis Assoc Disord. 2015 Oct 17; Authors: Grill JD, Karlawish J


Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding.

Neurol Genet. 2015 Oct; Authors: Lazaris A, Hwang KS, Goukasian N, Ramirez LM, Eastman J, Blanken AE, Teng E, Gylys K, Cole G, Saykin AJ, Shaw LM, Trojanowski JQ, Jagust WJ, Weiner MW, Apostolova LG, Alzheimer's Disease Neuroimaging Initiative


A review of ethical issues in dementia.

Int Psychogeriatr. 2015 Oct; Authors: Johnson RA, Karlawish J


Ascertaining Subjective Cognitive Decline: A Comparison of Approaches and Evidence for Using an Age-Anchored Reference Group.

J Alzheimers Dis. 2015 Sep 24; Authors: Tandetnik C, Farrell MT, Cary MS, Cines S, Emrani S, Karlawish J, Cosentino S


Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.

Brain. 2015 Sep 15; Authors: Portelius E, Zetterberg H, Skillbäck T, Törnqvist U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM, Mattsson N, Blennow K, Alzheimer’s Disease Neuroimaging Initiative


Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects.

J Alzheimers Dis. 2015 Sep 9; Authors: Lewczuk P, Kornhuber J, Toledo JB, Trojanowski JQ, Knapik-Czajka M, Peters O, Wiltfang J, Shaw LM


Suspected non-AD pathology in mild cognitive impairment.

Neurobiol Aging. 2015 Sep 7; Authors: Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN, Yushkevich PA, Wolk DA, Alzheimer's Disease Neuroimaging Initiative


Neuropathology and Cellular Pathogenesis of Spinocerebellar Ataxia Type 12.

Mov Disord. 2015 Sep 4; Authors: O'Hearn EE, Hwang HS, Holmes SE, Rudnicki DD, Chung DW, Seixas AI, Cohen RL, Ross CA, Trojanowski JQ, Pletnikova O, Troncoso JC, Margolis RL


Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.

J Alzheimers Dis. 2015 Sep 3; Authors: Bilello M, Doshi J, Nabavizadeh SA, Toledo JB, Erus G, Xie SX, Trojanowski JQ, Han X, Davatzikos C


Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study.

Alzheimers Dement (Amst). 2015 Sep 1; Authors: Leung YY, Toledo JB, Nefedov A, Polikar R, Raghavan N, Xie SX, Farnum M, Schultz T, Baek Y, Deerlin VV, Hu WT, Holtzman DM, Fagan AM, Perrin RJ, Grossman M, Soares HD, Kling MA, Mailman M, Arnold SE, Narayan VA, Lee VM, Shaw LM, Baker D, Wittenberg GM, Trojanowski JQ, Wang LS


Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Brain. 2015 Sep; Authors: Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ, Alzheimer’s Disease Neuroimaging Initiative


Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections.

Acta Neuropathol. 2015 Sep; Authors: Iba M, McBride JD, Guo JL, Zhang B, Trojanowski JQ, Lee VM


Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease.

Alzheimers Dement. 2015 Aug 29; Authors: Montine TJ, Monsell SE, Beach TG, Bigio EH, Bu Y, Cairns NJ, Frosch M, Henriksen J, Kofler J, Kukull WA, Lee EB, Nelson PT, Schantz AM, Schneider JA, Sonnen JA, Trojanowski JQ, Vinters HV, Zhou XH, Hyman BT


The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment.

Soc Sci Med. 2015 Aug 18; Authors: Johnson R, Harkins K, Cary M, Sankar P, Karlawish J


Memory, executive, and multidomain subtle cognitive impairment: Clinical and biomarker findings.

Neurology. 2015 Jul 14; Authors: Toledo JB, Bjerke M, Chen K, Rozycki M, Jack CR, Weiner MW, Arnold SE, Reiman EM, Davatzikos C, Shaw LM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative


Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Alzheimers Dement. 2015 Jul; Authors: Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Donohue MC, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw L, Thompson PM, Toga AW, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative


The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

Alzheimers Dement. 2015 Jul; Authors: Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen PS, Saykin AJ, Weiner MW, Trojanowski JQ, Shaw LM, Alzheimer's Disease Neuroimaging Initiative


Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.

Nat Commun. 2015 June 16; Authors: Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NC, Yoon H, Kim J, Fujioka S, McLean CA, Ghetti B, Spina S, Cantwell LB, Farlow MR, Grafman J, Huey ED, Ryung Han M, Beecher S, Geller ET, Kretzschmar HA, Roeber S, Gearing M, Juncos JL, Vonsattel JP, Van Deerlin VM, Grossman M, Hurtig HI, Gross RG, Arnold SE, Trojanowski JQ, Lee VM, Wenning GK, White CL, Höglinger GU, Müller U, Devlin B, Golbe LI, Crook J, Parisi JE, Boeve BF, Josephs KA, Wszolek ZK, Uitti RJ, Graff-Radford NR, Litvan I, Younkin SG, Wang LS, Ertekin-Taner N, Rademakers R, Hakonarsen H, Schellenberg GD, Dickson DW


High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.

Acta Neuropathol Commun. 2015 June 4; Authors: Wheeler JM, McMillan PJ, Hawk M, Iba M, Robinson L, Xu GJ, Dombroski BA, Jeong D, Dichter MA, Juul H, Loomis E, Raskind M, Leverenz JB, Trojanowski JQ, Lee VM, Schellenberg GD, Kraemer BC


2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Alzheimers Dement. 2015 Jun; Authors: Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative


Examining the Pathways between Self-Awareness and Well-Being in Mild to Moderate Alzheimer Disease.

Am J Geriatr Psychiatry. 2015 May 19; Authors: Cines S, Farrell M, Steffener J, Sullo L, Huey E, Karlawish J, Cosentino S


Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

JAMA. 2015 May 19; Authors: Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ, Amyloid PET Study Group, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sánchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chételat G, Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ


Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

JAMA. 2015 May 19; Authors: Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H


Relationship of contextual cueing and hippocampal volume in amnestic mild cognitive impairment patients and cognitively normal older adults.

J Int Neuropsychol Soc. 2015 Apr; Authors: Negash S, Kliot D, Howard DV, Howard JH, Das SR, Yushkevich PA, Pluta JB, Arnold SE, Wolk DA

Subscribe to this RSS Feed